Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0, while the study record remains unavailable and displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T13:53:58.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T13:31:10.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov study page still displays a 403 Forbidden error. Its footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T13:51:21.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T14:58:06.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content with a basic error screen and removing navigation to the study details.
    Difference
    19%
    Check dated 2026-09-20T20:08:25.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.6.6, replacing the previous revision label, indicating a newer version of the study page.
    Difference
    0.1%
    Check dated 2026-08-30T22:27:51.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.